Clinical Data gets app nod for depression drug

(AP) -- Federal regulators have accepted an application for a depression drug marketed by Clinical Data Inc., the company said Monday.

The acceptance of vilazodone, officially made Friday by the , triggered a $15.6 million payment by Clinical Data to Merck Serono, which developed the drug.

In June 2009, Clinical Data said vilazodone met its goals in a late-stage clinical trial as a treatment for major .

Merck Serono is a unit of German drug maker Merck KGaA, and is not connected to New Jersey-based Merck and Co.


Explore further

Merck's heart failure drug misses trial goals

©2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Citation: Clinical Data gets app nod for depression drug (2010, May 24) retrieved 18 January 2022 from https://medicalxpress.com/news/2010-05-clinical-app-depression-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors